IN this study it is reported that: (1) the levels of blood platelet-activating factor and serum tumour necrosis factor significantly increased after coronary ligation and reperfusion, compared with sham-ligated controls, in an anaesthetized rat model; (2) compared with vehicle controls, pretreatment with the PAF antagonist BN 50739 (10 mg/kg, i.v.) produced significant decreases in infarct size (from 29.6 + 4.0% to 22.4 + 2.1%, p < 0.05 after 3 h ligation, and from 28.5 + 9.5% to 10.5 + 4.5%, p < 0.01 after 4 h reperfusion) and the level of serum TNF (from 10.4 + 7.7 U/ml to 3.9 + 4.8 U/ml, p < 0.05); and (3) 
Introduction
Evidence has recently been accumulated that platelet-activating factor (PAF) may contribute to myocardial ischaemia and reperfusion injury. It has been found that the myocardial infarct size, the incidence of arrhythmias and the mortality increase after exogenous administration of PAF to animals, and that the level of serum tumour necrosis factor (TNF) markedly increases in patients with acute myocardial infarction. However, the implication of increasing level of TNF and the relationship between PAF and TNF in myocardial ischaemia and reperfusion injury remain unclear. In order to explore the possible role of, and interaction between, PAF and TNF in myocardial ischaemia and reperfusion injury, the authors investigated: (1) 
Discussion
In this study it was found that the level of blood PAF in the rats with coronary artery ligation from 1 to 4 h increased significantly, and increased further in the rats subjected to 40 min coronary ligation followed by a 4 h reperfusion, indicating that synthesis and release of PAF may increase during acute 
